---
layout: default
title: Alfuzosin Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 63
evidence_level: L5
indication_count: 0
---

# Alfuzosin Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosin Hydrochloride: Repurposing Evaluation — Insufficient Data to Complete Assessment

## One-Sentence Summary

Alfuzosin hydrochloride is a selective alpha-1 adrenergic receptor antagonist widely used internationally for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
The current Evidence Pack contains **no TxGNN predicted indications** for this drug, and the drug has **no registered products in Singapore**, meaning a full repurposing evaluation cannot be completed at this stage.
This report documents existing data gaps and outlines the actions required before proceeding.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no Singapore registrations on record) |
| Predicted New Indication | None — TxGNN returned no predictions in this Evidence Pack |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

> No safety data (warnings, contraindications, or drug interactions) is available in this Evidence Pack. All safety fields are marked as data gaps, and the DDI query returned zero results.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is critically incomplete — TxGNN returned no predicted indications, no Singapore regulatory registrations exist, and key inputs (MOA, safety warnings, contraindications) are all absent. There is no repurposing signal to evaluate at this time.

**To proceed, the following is needed:**

- **TxGNN predictions**: Re-run the repurposing pipeline with the correct DrugBank ID for Alfuzosin Hydrochloride to generate candidate indications and confidence scores
- **DrugBank ID resolution**: The `drugbank_id` field is null — retrieve the correct ID (likely DB00346) and re-query to populate MOA, categories, and toxicity data
- **Safety data**: Download and parse the prescribing information PDF to extract key warnings, contraindications, and drug interaction profiles
- **Regulatory verification**: Confirm whether Alfuzosin Hydrochloride has any pending or historical registrations in Singapore through the HSA product registry
- **Original indication documentation**: Record the approved indication (BPH / LUTS) as baseline context for any future mechanistic cross-indication analysis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

